Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant

References

[1] Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, Huang J, He N, Yu H, Lin X, Wei S, Wu T. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA 2020; 323(19): 1915–1923

[2] One World in Data. Coronavirus (COVID-19) Vaccinations, England. 2022

[3] Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022; 22(9): 1293–1302

[4] Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, Takhar H, Ogun OA, Simmons S, Zamparo JM, Jodar L, McLaughlin JM. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis 2022; 22(12): 1663–1665

[5] Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell AM, Simons D, Blomquist PB, Zaidi A, Nash S, Iwani Binti Abdul Aziz N, Thelwall S, Dabrera G, Myers R, Amirthalingam G, Gharbia S, Barrett JC, Elson R, Ladhani SN, Ferguson N, Zambon M, Campbell CNJ, Brown K, Hopkins S, Chand M, Ramsay M, Lopez Bernal J. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 2022; 386(16): 1532–1546

[6] Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, Ren J, Li Z, Guo X, Tao F, Chen J, Lu D, Sun X, Wang W. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. BMC Med 2022; 20(1): 400

[7] Lin DY, Gu Y, Xu Y, Wheeler B, Young H, Sunny SK, Moore Z, Zeng D. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. JAMA 2022; 328(14): 1415–1426

[8] Mallapaty S. China’s COVID vaccines have been crucial—now immunity is waning. Nature 2021; 598(7881): 398–399

[9] Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: who to vaccinate first? Sci Adv 2021; 7(6): eabf1374 doi:10.1126/sciadv.abf1374

[10] Omer SB, Malani PN. Booster vaccination to prevent COVID-19 in the era of Omicron: an effective part of a layered public health approach. JAMA 2022; 327(7): 628–629

[11] World Health Organization. COVID-19 vaccination roll-out stagnates in Africa. 2022

[12] Central People’s Government of the People’s Republic of China. The press conference for the control and prevention of COVID-19 Epidemic, China. 2021

[13] Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396(10249): 479–488

[14] FuZLiangDZhangWShiDMaYWeiDXiJYangSXuXTianDZhuZGuoMJiangLYuSWangSJiangFLingYWangSChenSLiuFTanYFanX. Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai. Front Med 2023; [Epub ahead of print]

[15] Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020; 92(7): 791–796

[16] Zhang JJ, Cao YY, Tan G, Dong X, Wang BC, Lin J, Yan YQ, Liu GH, Akdis M, Akdis CA, Gao YD. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy 2021; 76(2): 533–550

[17] Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis 2022; 114: 252–260

[18] Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet 2022; 399(10327): 814–823

[19] Adab P, Haroon S, O’Hara ME, Jordan RE. Comorbidities and covid-19. BMJ 2022; 377: o1431

[20] Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, Chevinsky JR, Schieber LZ, Summers AD, Lavery AM, Preston LE, Danielson ML, Cui Z, Namulanda G, Yusuf H, Mac Kenzie WR, Wong KK, Baggs J, Boehmer TK, Gundlapalli AV. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021. Prev Chronic Dis 2021; 18: 210123

[21] World Health Organization. COVID-19 vaccines technical documents. 2021

[22] Utami A, Margawati A, Pramono D, Nugraheni A, Pramudo SG. Determinant factors of COVID-19 vaccine hesitancy among adult and elderly population in Central Java, Indonesia. Patient Prefer Adherence 2022; 16: 1559–1570

[23] Choi WS, Cheong HJ. COVID-19 vaccination for people with comorbidities. Infect Chemother 2021; 53(1): 155–158

[24] Tsai R, Hervey J, Hoffman K, Wood J, Johnson J, Deighton D, Clermont D, Loew B, Goldberg SL. COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, or other serious comorbid conditions: cross-sectional, internet-based survey. JMIR Public Health Surveill 2022; 8(1): e29872

[25] Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, Chen B, Calzavara A, Fell DB, Austin PC, Wilson K, Schwartz KL, Brown KA, Gubbay JB, Basta NE, Mahmud SM, Righolt CH, Svenson LW, MacDonald SE, Janjua NZ, Tadrous M, Kwong JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ 2021; 374: n1943

[26] Paternina-Caicedo A, Jit M, Alvis-Guzmán N, Fernández JC, Hernández J, Paz-Wilches JJ, Rojas-Suarez J, Dueñas-Castell C, Alvis-Zakzuk NJ, Smith AD, Hoz-Restrepo F. Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. Lancet Reg Health Am 2022; 12: 100296

[27] Lu G, Zhang Y, Zhang H, Ai J, He L, Yuan X, Bao S, Chen X, Wang H, Cai J, Wang S, Zhang W, Xu J. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. Emerg Microbes Infect 2022; 11(1): 2045–2054

[28] Coppeta L, Balbi O, Grattagliano Z, Mina GG, Pietroiusti A, Magrini A, Bolcato M, Trabucco Aurilio M. First dose of the BNT162b2 mRNA COVID-19 vaccine reduces symptom duration and viral clearance in healthcare workers. Vaccines (Basel) 2021; 9(6): 659

[29] JohnsHopkins University COVID-19 Resource Center. COVID-19 dashboard by the center for systems science and engineering at Johns Hopkins University, the USA. 2022

[30] Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J, Mlisana K, Moultrie H. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 2022; 376(6593): eabn4947

[31] Eythorsson E, Runolfsdottir HL, Ingvarsson RF, Sigurdsson MI, Palsson R. Rate of SARS-CoV-2 reinfection during an omicron wave in Iceland. JAMA Netw Open 2022; 5(8): e2225320

[32] Mensah AA, Lacy J, Stowe J, Seghezzo G, Sachdeva R, Simmons R, Bukasa A, O’Boyle S, Andrews N, Ramsay M, Campbell H, Brown K. Disease severity during SARS-CoV-2 reinfection: a nationwide study. J Infect 2022; 84(4): 542–550

[33] Medić S, Anastassopoulou C, Lozanov-Crvenković Z, Vuković V, Dragnić N, Petrović V, Ristić M, Pustahija T, Gojković Z, Tsakris A, Ioannidis JPA. Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: a population-level observational study. Lancet Reg Health Eur 2022; 20: 100453

[34] WangHYuanYWuBXiaoMWangZDiaoTZengRChenLLeiYLongPGuoYLaiXWenYLiWCaiHSongLNiWZhaoYOuyangKWangJWangQLiuLWangCPanALiXGongRWuT. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents. Front Med 2023; [Epub ahead of print]

[35] Carreño JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, Sominsky LA, Clark JJ, Adelsberg DC, Bielak DA, Gonzalez-Reiche AS, Dambrauskas N, Vigdorovich V; PSP-PARIS Study Group; Srivastava K, Sather DN, Sordillo EM, Bajic G, van Bakel H, Simon V, Krammer F. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 2022; 602(7898): 682–688

RIGHTS & PERMISSIONS

Higher Education Press